| 前收市價 | 109.93 |
| 開市 | 110.04 |
| 買盤 | 110.40 x 800 |
| 賣出價 | 113.55 x 800 |
| 今日波幅 | 109.67 - 110.66 |
| 52 週波幅 | 92.19 - 112.48 |
| 成交量 | |
| 平均成交量 | 1,372,341 |
| 市值 | 223.352B |
| Beta 值 (5 年，每月) | 0.49 |
| 市盈率 (最近 12 個月) | 22.56 |
| 每股盈利 (最近 12 個月) | 4.89 |
| 業績公佈日 | 2024年7月18日 |
| 遠期股息及收益率 | 3.78 (3.44%) |
| 除息日 | 2024年3月07日 |
| 1 年預測目標價 | 114.26 |
ZacksIs a Beat in the Cards for Incyte (INCY) in Q2 Earnings?
On Incyte's (INCY) second-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its lead drug, Jakafi, which has been facing stiff competition.
ZacksThese 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
ZacksIonis (IONS) Completes Enrolment for Rare Disease Drug Study
Ionis' (IONS) late-stage study is evaluating zilganersen in a rare neurological disorder called Alexander disease. Top-line data from this study is expected by the end of the next year.
